Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III EGFR-mutant NSCLC: A Randomized Phase 2 Trial
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S82
DOI: 10.1016/j.ijrobp.2026.06.093 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von L. Wang und 15 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, L., Ning, F., Chen, L., Gao, A., Zhao, F., Wang, S., Wang, S., Yang, Z., Liao, X., Liu, C., Zhou, H., Li, P., Rao, C., Zhao, L., Lai, F., & Yu, C. (2026). Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III EGFR-mutant NSCLC: A Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics, 126(1), S82. https://doi.org/10.1016/j.ijrobp.2026.06.093
Vancouver
Wang L, Ning F, Chen L, Gao A, Zhao F, Wang S, et al. Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III EGFR-mutant NSCLC: A Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S82. doi:10.1016/j.ijrobp.2026.06.093
BibTeX
@article{Wang2026,
author = {Wang, L. and Ning, F. and Chen, L. and Gao, A. and Zhao, F. and Wang, S. and Wang, S. and Yang, Z. and Liao, X. and Liu, C. and Zhou, H. and Li, P. and Rao, C. and Zhao, L. and Lai, F. and Yu, C.},
title = {Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III EGFR-mutant NSCLC: A Randomized Phase 2 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S82},
doi = {10.1016/j.ijrobp.2026.06.093}
}
EUVIMED